VKTX
Viking Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$34.51
+1.57%Jul 29, 2026, 20:05 UTC
Viking Therapeutics announced its financial results for the second quarter and six months ended June 30, 2026.
Jun 25, 2026, 15:01 UTC
Viking Therapeutics initiated a Phase I clinical study for its new obesity drug VK3019.
Source:Jun 11, 2026, 11:05 UTC
Viking Therapeutics appointed Hubert C. Chen, M.D. as a new executive.
Source: